Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data on kidney drug finerenone in chinese patients

NCT ID NCT07124039

Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed electronic health records from over 6,500 patients in China who started taking finerenone for chronic kidney disease and type 2 diabetes. Researchers tracked kidney function, potassium levels, and side effects like high potassium. The goal was to see how the drug performs in everyday medical practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Finerenone (Kerendia)
What this could lead to
If successful, this study could provide doctors with better information on how to safely use finerenone in everyday practice for patients with diabetic kidney disease.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to patients outside of China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

6,537 people

The number who actually took part.

Started

Jul 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with chronic kidney disease and type 2 diabetes mellitus who initiate finerenone treatment in China

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Minimum of 12 months continuous enrolment before the index date in the database with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the electronic health record system * No recorded prescription of finerenone prior to the index date * Age 18 years or older as of the index date * Diabetic kidney disease diagnosis by diagnosis texts at any point before (and including) the index date, OR * T2D diagnosis at any point before (and including) the index date using the same algorithms as in previous studies of the FIRST program, AND * CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date: * A diagnosis code/text indicating CKD stage 2, 3, 4, or stage unspecified OR * Two UACR test results ≥30 mg/g separated by at least 90 days and no more than 548 days. OR • Two different eGFR test results ≥15 mL/min/1.73 m2 AND \<60 mL/min/1.73 m2 separated by at least 90 days and no more than 548 days. Exclusion criteria * Type 1 diabetes mellitus identified by diagnosis codes/texts in the patient record on or before the index date * Kidney cancer identified by diagnosis codes/texts on or before the index date * Kidney failure on or before the index date, defined as: * Two different eGFR test results \<15 mL/min/1.73 m2 separated by at least 90 days and no more than 548 days OR * Dependence on dialysis (at least 3 sessions over at least 90 days during the baseline period) OR * A diagnosis code/text indicating kidney failure or CKD stage 5 OR * A recorded diagnosis indicating kidney transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Type 2 diabetes mellitus

Contacts and locations

Locations

  • Inspur Tianjin Regional Electronic Health Records Database

    Tianjin, Tianjin Municipality, 301799, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.